-
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Hit US$6.64B by 2033, Industry Developments, Future Growth
13 Oct 2025 14:02 GMT
… ;global-dunche-muscular-dystrophy-therapeutics-market
Key Highlights – Duchenne Muscular Dystrophy Therapeutics Market
North … ;customize/global-dunche-muscular-dystrophy-therapeutics-market
Duchenne Muscular Dystrophy (DMD) Treatment Market …
-
Satellos reports safety data of SAT-3247 in Duchenne muscular dystrophy trial
13 Oct 2025 17:58 GMT
… 20–27 years with Duchenne muscular dystrophy (DMD).
Data from the Phase … progression typically observed in Duchenne muscular dystrophy within this age group.
A …
-
Global Duchenne Muscular Dystrophy Therapeutics Market to hit $ 6.64 billion by 2033 with Gene Therapy innovations
13 Oct 2025 13:46 GMT
… ;global-dunche-muscular-dystrophy-therapeutics-market
The Duchenne Muscular Dystrophy (DMD) … Market Segmentation
The Duchenne Muscular Dystrophy therapeutics market is segmented … ?report=global-dunche-muscular-dystrophy-therapeutics-market
Regional …
-
AskBio reports AB-1003 safety data for limb-girdle muscular dystrophy
13 Oct 2025 10:56 GMT
… AB-1003 for limb-girdle muscular dystrophy (LGMD) 2I/R9.
This … effective treatment for limb-girdle muscular dystrophy.”
The dose-escalation, placebo-controlled …
-
AskBio presents interim safety results from phase 1/phase 2 LION─CS101 clinical trial of AB─1003 in participants with limb─girdle muscular dystrophy 2I/R9
13 Oct 2025 08:59 GMT
… in participants with limb-girdle muscular dystrophy (LGMD) 2I/R9 at … effective treatment for limb-girdle muscular dystrophy.”
The LION-CS101 clinical trial …
-
STAT+: Sarepta to seek approval for gene therapy in rare form of muscular dystrophy
11 Oct 2025 00:32 GMT
… an ultra-rare form of muscular dystrophy, according to data the company … disease, known as limb-girdle muscular dystrophy (LGMD) 2E. That would make … approved gene therapy for Duchenne muscular dystrophy, Elevidys, and experimental gene therapies …
-
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
10 Oct 2025 13:54 GMT
… 27 years) with Duchenne muscular dystrophy (Duchenne or DMD) … all stages of Duchenne muscular dystrophy. J Neurol. 267 … outcome measures in Duchenne muscular dystrophy: Long-term natural history … is lost in Duchenne muscular dystrophy and other degenerative or …
-
AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9
10 Oct 2025 12:00 GMT
… effective treatment for limb-girdle muscular dystrophy.” The LION-CS101 clinical … congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’ … – Autosomal recessive limb-girdle muscular dystrophy type 2i. Available at: https …
-
<![CDATA[Association Identified Between Vastus Lateralis Fat Fraction and Givinostat Treatment Response in Duchenne Muscular Dystrophy]]>
10 Oct 2025 00:31 GMT
… outcomes among patients with Duchenne muscular dystrophy (DMD) treated with givinostat … givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, … Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons …
-
<![CDATA[Post Hoc EPIDYS Analysis Shows Consistent Efficacy of Givinostat in Duchenne Muscular Dystrophy]]>
10 Oct 2025 00:30 GMT
… Givinostat Treatment Response in Duchenne Muscular Dystrophy
Givinostat, a histone deacetylase … Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy. FDA. News release. … fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy
3. Phan H, …
About
© 1995-2025